Articles from ElevateBio

Following nearly eight years as Chairman and CEO, Hallal will oversee CEO transition and continue to guide strategic, financial and operational priorities as Executive Chairman of the Board of Directors

WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, announced a multi-year collaboration with Amazon Web Services (AWS) to accelerate the discovery and development of CRISPR gene editing therapeutics through generative artificial intelligence (AI). ElevateBio aims to broaden the range of diseases addressable by gene editing therapies by combining the gene editing technologies and large CRISPR dataset of ElevateBio Life Edit – the Company’s gene editing and R&D technology business – with AWS’s advanced computing capabilities.

-  LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential wild-type HTT in a clinically relevant Huntington’s disease mouse model

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced that Chairman and Chief Executive Officer, David Hallal, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:00 a.m. PST.

Dr. Pooler brings decades of scientific leadership and expertise in the discovery and development of transformative genetic medicines

- Proprietary LNP platform delivered Life Edit gene editing system in murine studies, leading to high in vivo editing with low immunogenicity profile

-  Issued patents provide protection for multiple of Life Edit’s lead adenine deaminases, base editors, and RNA-guided nucleases with applications in base editing and reverse transcriptase editing

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, in Baltimore, MD. The poster presentations will detail ElevateBio’s expertise in optimizing the development and manufacturing of genetic medicines, including scalable screening and manufacturing processes for adeno-associated virus (AAV) vectors for gene therapies, a proprietary CAR/TCR platform that accelerates the nomination of therapeutic receptors for faster development of engineering cell therapies, and an efficient, scalable process to produce high purity circularRNA (circRNA) for potential therapeutic applications both ex vivo and in vivo.

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that Andrew Sandford has joined as President of ElevateBio BaseCamp, Inc., a purpose-built center of innovation dedicated to process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. Andrew brings over 20 years of experience in building, operating, and leading life science technology and manufacturing companies and will continue to extend the ElevateBio BaseCamp process development and manufacturing platform to foster strategic partnerships in the field of cell and gene therapy.

ElevateBio, LLC (ElevateBio), a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment (PTA). This patent, issued to LifeEDIT Therapeutics, Inc. (Life Edit), is the first to provide composition and methods of use protection for various RNA-guided nucleases (RGNs) in Life Edit’s gene editing platform. Life Edit is an ElevateBio company and holds an array of novel RGNs and base editors.

Boston Children’s Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.

ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that Margo Roberts, Ph.D., has joined the company as a Strategic Scientific Advisor. Dr. Roberts will provide her leading immunology research, drug discovery, and development expertise to the company as it builds out a comprehensive immunotherapy platform on behalf of its portfolio companies and strategic partners.

ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that ElevateBio BaseCamp has been selected as the 2021 Facility of the Year Awards (FOYA) Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering (ISPE). Winners in this category exemplify the application of modern management techniques aimed to improve operating efficiencies, promote excellent quality, consistency and yield competitive cost of goods from existing and new facilities, processes, and manufacturing operations.